Johnson & Johnson (JNJ) Cash & Equivalents (2009 - 2026)

Johnson & Johnson has disclosed Cash & Equivalents across 18 years of filings, most recently posting $20.4 billion for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 9.93% year-over-year to $20.4 billion; the TTM figure through Jun 2026 stood at $20.4 billion (up 9.93% YoY), while the FY2025 annual figure was $19.7 billion, down 18.24% from the prior year.
• Cash & Equivalents came in at $20.4 billion for Q2 2026 at Johnson & Johnson, down from $21.7 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $38.5 billion in Q1 2025 to a low of $10.5 billion in Q2 2022.
• Average Cash & Equivalents over 5 years is $19.7 billion, with a median of $19.7 billion recorded in 2023.
• Year-over-year, Cash & Equivalents surged 92.87% in 2023 and sank 43.63% in 2026.
• Over 5 years, Cash & Equivalents stood at $11.4 billion in 2022, then soared by 92.51% to $21.9 billion in 2023, then increased by 10.27% to $24.1 billion in 2024, then fell by 18.24% to $19.7 billion in 2025, then gained by 3.62% to $20.4 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $20.4 billion in Q2 2026, $21.7 billion in Q1 2026, and $19.7 billion in Q4 2025.